Bone morphogenetic protein-inducer tilorone identified by high-throughput screening is antifibrotic in vivo

American Journal of Respiratory Cell and Molecular Biology

Volumn 48, Issue 4, 2013, Pages 448-455

  Leppäranta, Outi ^a   Tikkanen, Jussi M ^a,b   Bespalov, Maxim M ^c,d   Koli, Katri ^b,c   Myllärniemi, Marjukka ^a,b  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c UNIVERSITY OF HELSINKI   (Finland)

^d SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Bone morphogenetic proteins; High throughput screening; Idiopathic pulmonary fibrosis; Tilorone; Transforming growth factor

Indexed keywords

ANTIFIBROTIC AGENT; BONE MORPHOGENETIC PROTEIN; COLLAGEN TYPE 1; COLLAGEN TYPE 1A1; COLLAGEN TYPE 3A1; HYDROXYPROLINE; INHIBITOR OF DIFFERENTIATION 3; OSTEOGENIC PROTEIN 1; SILICON DIOXIDE; SMAD PROTEIN; TILORONE; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BMP7 PROTEIN, HUMAN; BMP7 PROTEIN, MOUSE; COLLAGEN TYPE I, ALPHA 1 CHAIN; ID3 PROTEIN, HUMAN; IDB3 PROTEIN, MOUSE; INHIBITOR OF DIFFERENTIATION PROTEIN; TUMOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DISEASE COURSE; DRUG ACTIVITY; EPITHELIUM CELL; GENE EXPRESSION; HIGH THROUGHPUT SCREENING; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VIVO STUDY; LUNG ALVEOLUS EPITHELIUM; LUNG FIBROSIS; LUNG PARENCHYMA; MOLECULAR LIBRARY; MOUSE; NONHUMAN; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; ANIMAL; BIOSYNTHESIS; DRUG EFFECT; DRUG SCREENING; FIBROSING ALVEOLITIS; GENE EXPRESSION REGULATION; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; BONE MORPHOGENETIC PROTEIN 7; CELL LINE, TUMOR; COLLAGEN TYPE I; DRUG EVALUATION, PRECLINICAL; GENE EXPRESSION REGULATION; IDIOPATHIC PULMONARY FIBROSIS; INHIBITOR OF DIFFERENTIATION PROTEINS; MICE; NEOPLASM PROTEINS; SIGNAL TRANSDUCTION; TILORONE;

MLCS; MLOWN;

EID: 84878245379     PISSN: 10441549     EISSN: 15354989     Source Type: Journal    
DOI: 10.1165/rcmb.2012-0201OC     Document Type: Article

References (53)

1. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, Lasky JA, et al. ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis: an official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011;183: 788-824.
2. Noble PW, Albera C, BradfordWZ, Costabel U, Glassberg MK, Kardatzke D, King TE Jr, Lancaster L, Sahn SA, Szwarcberg J, et al. CAPACITY Study Group: pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 2011;377: 1760-1769.
3. Azuma A, Nukiwa T, Tsuboi E, Suga M, Abe S, Nakata K, Taguchi Y, Nagai S, Itoh H, Ohi M, et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2005;171: 1040-1047.
4. Taniguchi H, Ebina M, Kondoh Y, Ogura T, Azuma A, Suga M, Taguchi Y, Takahashi H, Nakata K, Sato A, et al. Pirfenidone Clinical Study Group in Japan: pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J 2010;35: 821-829.
5. Richeldi L, Costabel U, Selman M, Kim DS, Hansell DM, Nicholson AG, Brown KK, Flaherty KR, Noble PW, Raghu G, et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med 2011;365: 1079-1087.
6. Bartram U, Speer CP. The role of transforming growth factor beta in lung development and disease. Chest 2004;125: 754-765.
7. Sime PJ, O'Reilly KM. Fibrosis of the lung and other tissues: new concepts in pathogenesis and treatment. Clin Immunol 2001;99: 308-319.
8. Sheppard D. Transforming growth factor beta: a central modulator of pulmonary and airway inflammation and fibrosis. Proc Am Thorac Soc 2006;3: 413-417.
9. Kawabata M, Imamura T, Miyazono K. Signal transduction by bone morphogenetic proteins. Cytokine Growth Factor Rev 1998;9: 49-61.
10. Shannon JM, Hyatt BA. Epithelial-mesenchymal interactions in the developing lung. Annu Rev Physiol 2004;66: 625-645.
11. Masterson JC, Molloy EL, Gilbert JL, McCormack N, Adams A, O'Dea S. Bone morphogenetic protein signalling in airway epithelial cells during regeneration. Cell Signal 2011;23: 398-406.
12. Koli K, Myllarniemi M, Vuorinen K, Salmenkivi K, Ryynanen MJ, Kinnula VL, Keski-Oja J. Bone morphogenetic protein-4 inhibitor Gremlin is overexpressed in idiopathic pulmonary fibrosis. Am J Pathol 2006;169: 61-71.
13. Myllarniemi M, Lindholm P, Ryynanen MJ, Kliment CR, Salmenkivi K, Keski-Oja J, Kinnula VL, Oury TD, Koli K. Gremlin-mediated decrease in bone morphogenetic protein signaling promotes pulmonary fibrosis. Am J Respir Crit Care Med 2008;177: 321-329.
14. Korchynskyi O, ten Dijke P. Identification and functional characterization of distinct critically important bone morphogenetic protein-specific response elements in the Id1 promoter. J Biol Chem 2002;277: 4883-4891.
15. Dennler S, Itoh S, Vivien D, ten Dijke P, Huet S, Gauthier JM. Direct binding of Smad3 and Smad4 to critical TGF beta-inducible elements in the promoter of human plasminogen activator inhibitor-Type 1 gene. EMBO J 1998;17: 3091-3100.
16. Zhang JH, Chung TD, Oldenburg KR. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen 1999;4: 67-73.
17. Lakatos HF, Burgess HA, Thatcher TH, Redonnet MR, Hernady E, Williams JP, Sime PJ. Oropharyngeal aspiration of a silica suspension produces a superior model of silicosis in the mouse when compared to intratracheal instillation. Exp Lung Res 2006;32: 181-199.
18. Golovenko NY, Borisyuk IY. Pharmacokinetics of amixin after repeated peroral administration to mice. Bull Exp Biol Med 2005;140: 708-710.
19. Zinkovsky VG, Zhuk OV, Sumriy SK. Pharmacokinetics of a synthetic interferon inducer amixin in mice. Pharmacol Rep 2007;59: 739-751.
20. Mayer-Sonnenfeld T, Avrahami D, Friedman-Levi Y, Gabizon R. Chemically induced accumulation of GAGs delays PrP(sc) clearance but prolongs prion disease incubation time. Cell Mol Neurobiol 2008;28: 1005-1015.
21. Reddy GK, Enwemeka CS. A simplified method for the analysis of hydroxyproline in biological tissues. Clin Biochem 1996;29: 225-229.
22. Zeisberg M, Muller GA, Kalluri R. Are there endogenous molecules that protect kidneys from injury? The case for bone morphogenic protein-7 (BMP-7). Nephrol Dial Transplant 2004;19: 759-761.
23. Bertin G, Averbeck D. Cadmium: cellular effects, modifications of biomolecules, modulation of DNA repair and genotoxic consequences (a review). Biochimie 2006;88: 1549-1559.
24. Peltonen K, Colis L, Liu H, Jaamaa S, Moore HM, Enback J, Laakkonen P, Vaahtokari A, Jones RJ, af Hallstrom TM, et al. Identification of novel p53 pathway activating small-molecule compounds reveals unexpected similarities with known therapeutic agents. PLoS ONE 2010;5:e12996.
25. Hsu DR, Economides AN, Wang X, Eimon PM, Harland RM. The Xenopus dorsalizing factor Gremlin identifies a novel family of secreted proteins that antagonize BMP activities. Mol Cell 1998;1: 673-683.
26. Moeller A, Ask K, Warburton D, Gauldie J, Kolb M. The bleomycin animal model: a useful tool to investigate treatment options for idiopathic pulmonary fibrosis? Int J Biochem Cell Biol 2008;40: 362-382.
27. Noble PW. Idiopathic pulmonary fibrosis: natural history and prognosis. Clin Chest Med 2006;27:S11-S16. (v.).
28. Taniguchi H, Kondoh Y, Ebina M, Azuma A, Ogura T, Taguchi Y, Suga M, Takahashi H, Nakata K, Sato A, et al. Pirfenidone Clinical Study Group in Japan: the clinical significance of 5% change in vital capacity in patients with idiopathic pulmonary fibrosis: extended analysis of the pirfenidone trial. Respir Res 2011;12:93.
29. Morrissey J, Hruska K, Guo G, Wang S, Chen Q, Klahr S. Bone morphogenetic protein-7 improves renal fibrosis and accelerates the return of renal function. J Am Soc Nephrol 2002;13:S14-S21.
30. Zeisberg EM, Tarnavski O, Zeisberg M, Dorfman AL, McMullen JR, Gustafsson E, Chandraker A, Yuan X, Pu WT, Roberts AB, et al. Endothelial-to-mesenchymal transition contributes to cardiac fibrosis. Nat Med 2007;13: 952-961.
31. Kinoshita K, Iimuro Y, Otogawa K, Saika S, Inagaki Y, Nakajima Y, Kawada N, Fujimoto J, Friedman SL, Ikeda K. Adenovirus-mediated expression of BMP-7 suppresses the development of liver fibrosis in rats. Gut 2007;56: 706-714.
32. Sugimoto H, LeBleu VS, Bosukonda D, Keck P, Taduri G, Bechtel W, Okada H, Carlson W Jr, Bey P, Rusckowski M, et al. Activin-like kinase 3 is important for kidney regeneration and reversal of fibrosis. Nat Med 2012;18: 396-404.
33. Logeart-Avramoglou D, Bourguignon M, Oudina K, Ten Dijke P, Petite H. An assay for the determination of biologically active bone morphogenetic proteins using cells transfected with an inhibitor of differentiation promoter-luciferase construct. Anal Biochem 2006;349: 78-86.
34. Monteiro RM, de Sousa Lopes SM, Korchynskyi O, ten Dijke P, Mummery CL. Spatio-temporal activation of Smad1 and Smad5 in vivo: monitoring transcriptional activity of Smad proteins. J Cell Sci 2004;117: 4653-4663.
35. Krueger RE, Mayer GD. Tilorone hydrochloride: an orally active antiviral agent. Science 1970;169: 1213-1214.
36. Mayer GD, Krueger RF. Tilorone hydrochloride: mode of action. Science 1970;169: 1214-1215.
37. Chandra P, Zunino F, Gotz A. Bis-DEAE-fluorenone: a specific inhibitor of DNA polymerases from RNA tumor viruses. FEBS Lett 1972;22: 161-164.
38. Megel H, Raychaudhuri A, Shemano I, Beaver TH, Thomas LL. The anti-inflammatory actions of tilorone hydrochloride. Proc Soc Exp Biol Med 1975;149: 89-93.
39. Tazulakhova EB, Parshina OV, Guseva TS, Ershov FI. Russian experience in screening, analysis, and clinical application of novel interferon inducers. J Interferon Cytokine Res 2001;21: 65-73.
40. Gurujeyalakshmi G, Giri SN. Molecular mechanisms of antifibrotic effect of interferon gamma in bleomycin-mouse model of lung fibrosis: downregulation of TGF-beta and procollagen I and III gene expression. Exp Lung Res 1995;21: 791-808.
41. Ziesche R, Hofbauer E, Wittmann K, Petkov V, Block LH. A preliminary study of long-term treatment with interferon gamma-1B and low-dose prednisolone in patients with idiopathic pulmonary fibrosis. N Engl J Med 1999;341: 1264-1269.
42. Nathan SD, Barnett SD, Moran B, Helman DL, Nicholson K, Ahmad S, Shorr AF. Interferon gamma-1B as therapy for idiopathic pulmonary fibrosis: an intrapatient analysis. Respiration 2004;71: 77-82.
43. Raghu G, Brown KK, Bradford WZ, Starko K, Noble PW, Schwartz DA, King TE Jr, Idiopathic Pulmonary Fibrosis Study Group. A placebo-controlled trial of interferon gamma-1B in patients with idiopathic pulmonary fibrosis. N Engl J Med 2004;350: 125-133.
44. King TE Jr, Albera C, Bradford WZ, Costabel U, Hormel P, Lancaster L, Noble PW, Sahn SA, Szwarcberg J, Thomeer M, et al. INSPIRE Study Group: effect of interferon gamma-1B on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial. Lancet 2009;374: 222-228.
45. Nishimura T, Okobira T, Kelly AM, Shimada N, Takeda Y, Sakurai K. DNA binding of tilorone: 1H NMR and calorimetric studies of the intercalation. Biochemistry 2007;46: 8156-8163.
46. Fischer J, Hein L, Lullmann-Rauch R, von Witzendorff B. Tiloroneinduced lysosomal lesions: the bisbasic character of the drug is essential for its high potency to cause storage of sulphated glycosaminoglycans. Biochem J 1996;315: 369-375.
47. Weiss JN, Weinberg RS, Regelson W. Keratopathy after oral administration of tilorone hydrochloride. Am J Ophthalmol 1980;89: 46-53.
48. Ratan RR, Siddiq A,Aminova L, Langley B, McConoughey S, Karpisheva K, Lee HH, Carmichael T, Kornblum H, Coppola G, et al. Small molecule activation of adaptive gene expression: tilorone or its analogs are novel potent activators of hypoxia inducible factor-1 that provide prophylaxis against stroke and spinal cord injury.AnnNYAcad Sci 2008;1147: 383-394.
49. Milroy LG, Zinzalla G, Loiseau F, Qian Z, Prencipe G, Pepper C, Fegan C, Ley SV. Natural-product-like spiroketals and fused bicyclic acetals as potential therapeutic agents for B-cell chronic lymphocytic leukaemia. ChemMedChem 2008;3: 1922-1935.
50. Xia M, Huang R, Sun Y, Semenza GL, Aldred SF, Witt KL, Inglese J, Tice RR, Austin CP. Identification of chemical compounds that induce HIF-1alpha activity. Toxicol Sci 2009;112: 153-163.
51. Keller TH, Shi PY, Wang QY. Anti-infectives: can cellular screening deliver? Curr Opin Chem Biol 2011;15: 529-533.
52. He K, Chan CB, Liu X, Jia Y, Luo HR, France SA, Liu Y, Wilson WD, Ye K. Identification of a molecular activator for insulin receptor with potent anti-diabetic effects. J Biol Chem 2011;286: 37379-37388.
53. Moorwood C, Lozynska O, Suri N, Napper AD, Diamond SL, Khurana TS. Drug discovery for Duchenne muscular dystrophy via utrophin promoter activation screening. PLoS ONE 2011;6:e26169.